Thanks to the generosity of countless supporters for the past ten years in honor of founder Diane Redington, The GCS Project is helping change what is possible for women battling… Read More »
Thanks to the generosity of countless supporters for the past ten years in honor of founder Diane Redington, The GCS Project is helping change what is possible for women battling… Read More »
Clinical trials are currently being offered at the University of Arkansas for Medical Sciences (UAMS). Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single… Read More »
Clinical trials are currently being offered at the University of Alabama at Birmingham. Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in… Read More »
Clinical trials are currently being offered at Medical University of South Carolina (MUSC) Health Care in Charleston SC. A Phase II/III Study of Paciltaxel/Carboplatin alone, or combined with either Trastuzumab… Read More »
Our sister never–not for a minute–lost hope. March marks the third anniversary we remember our sister, Diane Redington, who lost her courageous three-year battle to gynecologic carcinosarcoma (GCS/MMMT) on March… Read More »
Dr. Arend, an assistant professor and senior scientist at the University of Alabama at Birmingham has received funding from 2 drug companies – Bristol Meyers Squib and Exelixis to perform… Read More »
I am so incredibly proud to say that my mom is continuing to thrive, cancer-free. The words still seem foreign to me—‘cancer’ still pulls my heart to my throat, but… Read More »
Featured in Peoria Magazine. Hope. Our sister never—not for one minute—lost hope. March 15, 2021 marked the third anniversary we remembered our sister, Diane Redington, who lost her courageous three-year battle to gynecologic carcinosarcoma (GCS/MMMT).
A Phase 1b/2, Open Label Study of Rebastinib + Paclitaxel Combination for Patients with Advanced or Metastatic Solid Tumors NCT03601897 is a 2-part open label, Phase 1b/2, multicenter study of… Read More »
Dr. Arend, an assistant professor and senior scientist at the University of Alabama at Birmingham has received funding from 2 drug companies – Bristol Myers Squib and Exelixis to perform… Read More »